HER2-Negative Metastatic Breast Cancer
CASE 2: HER2-Negative Chemotherapy-Resistant mBC
Kim W, 53-year-old postmenopausal woman of Asian decent from Morristown, New Jersey, who worked as an accountant.
2013: Presented to PCP after finding a lump in right breast. Referred to oncologist for standard diagnostic workup.
Diagnosed with infiltrating ductal adenocarcinoma; 5.5-cm lesion in lower outer quadrant of right breast and palpable ipsilateral axillary nodes, which were FNA+ for adenocarcinoma
Fluorescence in situ hybridization determined HER2-negative/ER+/PR+ tumor
Patient was able to work and carry out daily activities (KPS score 94)
Bone scan and chest diagnostic CT revealed no metastases
Neoadjuvant therapy begun with dose-dense AC: doxorubicin 60 mg/m2 IV q2 weeks followed by weekly paclitaxel 80 mg/m2 x 12
Patient underwent breast-conserving therapy (malignant cells in 7 axillary lymph nodes)
Surgery followed by chest wall and regional lymph node radiation therapy (5x/week for 6 weeks). Started nonsteroidal aromatase inhibitor.
5 months after adjuvant chemotherapy treatment, patient complained of bone pain.
Patient was unable to work, but could carry out self care and some home upkeep
Bone scan and CT scan revealed several metastases: 2 lesions on right leg bone measuring 2-3 cm, 2 lesions on liver measuring 2-3 cm; 1 lesion on lung measuring 2-3 cm
Patient identified as potentially resistant to taxane (having progressed within 12 months of last adjuvant therapy)
Liver biopsy and pathology showed metastases consistent with original breast cancer. Patient diagnosed with stage IV cancer
Histology confirmed HER2-negative/ER+/PR+ disease. Began therapy with denosumab for bone metastases
Also received Xeloda 1000 mg/m2 PO BID day 1-14
Also received Xeloda 1000 mg/m2 PO BID day 1-14
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
Survival and Safety Outcomes Factor into Use of Sacituzumab Govitecan in HR+ Breast Cancer
March 29th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Experts Warn of Radiation Overtreatment in Older Women With Early-Stage Breast Cancer
March 20th 2024Studies have found that omitting radiation therapy after breast-conserving surgery and/or omitting axillary surgery in women age 70 years or older does not affect their survival when taking endocrine therapy.
Read More
Analyzing ADC Treatment Sequencing in Advanced Breast Cancer
March 15th 2024In the first article of a 2-part series, Virginia G. Kaklamani, MD, discussed her approach to biomarker testing and treatment sequencing for patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Read More